Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

NCT03768219 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Psoriasis
Ulcerative Colitis

Interventions

BIOLOGICAL: APVO210
BIOLOGICAL: Placebo

Sponsor

Aptevo Therapeutics